<DOC>
	<DOCNO>NCT00675623</DOCNO>
	<brief_summary>The Connection Study six-month confirmatory Phase 3 study determine safety efficacy Dimebon treatment mild-to-moderate Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>A Safety Efficacy Study Oral Dimebon Patients With Mild-To-Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>This study randomize , placebo-controlled 6-month study design adequate well-controlled trial demonstrate safety efficacy Dimebon treatment patient mild-to-moderate AD . Dimebon investigational drug Alzheimer 's disease . The target Dimebon 's mechanism action mitochondrion ( cell 's primary source energy ) .The Connection Study second two pivotal study evaluate effect Dimebon . It 6-month study enrol 525 patient United States , Europe , South America . All patient complete 6-month study eligible receive Dimebon open-label extension trial . The patient population carefully select ensure inclusion patient AD , rather type dementia . Mild-to-moderate disease define screen Mini-Mental State Examination ( MMSE ) . Patients attend study visit caregiver provide information patient 's condition .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>MildtoModerate Alzheimer 's disease Probable AD ( National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) Diagnostic Statistical Manual Mental DisordersIV ( DSMIV ) MMSE score 1024 inclusive Computerized tomography ( CT ) san magnetic resonance imaging ( MRI ) consistent AD Caregiver care patient least 5 day per week Antidementia drug include cholinesteraseinhibitors NmethylDaspartate receptor ( NMDA ) receptor antagonist within 90 day Other cause dementia Other primary psychiatric neurological disorder Unstable medical illness significant hepatic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Alzheimer 's disease , clinical trial , memory loss , mitochondrion ,</keyword>
	<keyword>investigational drug , neurodegenerative disease , dementia</keyword>
</DOC>